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 Hepatitis B virus (HBV), which belongs to the family 
Hepadnaviridae, causes hepatitis in humans with complications of liver 
cirrhosis and carcinoma, and HBV infection is a serious health problem. 
Seven proteins are encoded by HBV: preCore (preC-core), core, polymerase 
(pol), X (HBx), and three envelope proteins, L (PreS1-PreS2-S), M (PreS2-S) 
and S (HBs). HBV or HBV-related proteins are released from cells in 
multiple forms. Dane particles, which are mature infectious virions, are 
composed of an icosahedral nucleocapsid containing an incomplete double-
stranded DNA genome and core proteins wrapped by a viral envelope 
containing S, M and L. Subviral particles with circular or long shapes that 
are free from the nucleocapsid are found in patients’ sera. HBV proteins are 
also released in other forms such as HBe antigen, which is generated from 
preCore, and a Dane-like particle containing a variant core protein p22cr 
that is free from genomic DNA. A naked nucleocapsid without an envelope 
can also be released from cultured cells.  
In the case of enveloped viruses, expression of one or a few viral 
proteins causes shedding of viral protein-driven virus-like particles (VLPs) 
from cells. In the case of HBV, at least S and core proteins are known to be 
released from cells as VLPs when expressed alone. The use of VLPs could be 
an experimental measure to investigate the mechanism of virion formation. 
For the VLPs formed by the S protein (S-VLPs), we compared them 
with released HBV proteins by introducing HBV genomic DNA into cultured 
cells and with HBV-containing sera of a chronic HBV patient in terms of 
density and protein composition and we found that S-VLPs have properties 
similar to those of HBV subviral particles of HBV.  
 Tetherin, also named CD317, BST2 or HM1.24, is an interferon 
(IFN)-inducible protein that inhibits the release of human 
immunodeficiency virus (HIV), Ebola virus, Lassa virus, herpesvirus and 
other enveloped viruses from infected cells by tethering progeny virions to 
the membranes of host cells. We demonstrated that the release of VLPs by 
the M proteins of Nipah virus and Sendai virus is inhibited by tetherin. 
Furthermore, tetherin can induce NF-kB-mediated signal transduction that 
leads to the production of proinflammatory cytokines, thereby acting as an 
innate sensor of viral release. In the case of HBV, tetherin has also been 
shown to interact with the S protein and to moderately reduce HBV release 
from cultured cells. On the other hand, many viral proteins can inactivate 
tetherin in multiple ways. For example, HIV-1 Vpu can interact with 
tetherin via its transmembrane domain and downregulate tetherin from the 
plasma membrane. Ebola virus glycoprotein can directly bind to tetherin for 
antagonizing its function.  
In the present study, we showed that tetherin efficiently inhibits 
the release of S-VLPs. This inhibition was cancelled by co-expression of Vpu. 
On the other hand, tetherin did not significantly inhibit either the release of 
HBV or core-mediated virus-like particles (Core-VLPs). It was confirmed by 
fluorescent staining that the S protein and tetherin were colocalized in the 
cell. In the cultured cells carrying HBV genomic DNA and supporting 
continuous HBV replication (T23 cells), release of genomic DNA, which is an 
indicator of HBV mature particles, did not decrease even when tetherin was 
overexpressed. Furthermore, when tetherin was knocked down by siRNAs, 
there was no change in release of HBV DNA. In addition, in mice carrying 
human livers, expression of endogenous tetherin in the liver was moderately 
increased in HBV infection, while HBV continuously propagated in the liver. 
The growth of HBV did not appear to be significantly hindered even in the 
presence of tetherin. Therefore, the inhibitory effect of tetherin on virus in 
vivo was thought to be limited. Considering reports that the number of 
released subviral particle reaches 100,000 times more than that of 
infectious HBV particles, it is speculated that abundant subviral particles 
act as a decoy to protect HBV infectious particles from the action of tetherin. 
 The core protein is composed of the N-terminal assembly domain 
and the C-terminal arginine-rich domain (ARD). Core-VLPs are released as 
a naked capsid-like structure when the core protein is expressed in cultured 
cells like HuH-7 cells (data not shown). The mechanism of core-VLP release 
is unknown. The core protein is known to interact with Alix, a component of 
ESCRT (endosomal sorting complex required for transport). Core-VLP 
release is inhibited by co-expression of a dominant negative form of 
CHMP4B or Vps4A, which are components of the ESCRT system, and we 
also confirmed the results (data not shown).  
We then analyzed the interaction between the core mutant proteins 
and Alix. Core deletion mutants from the N-terminus and those from the C-
terminus indicated that the α-3 helix in the assembly domain is involved in 
the interaction. We further generated a series of core mutants in which 
three consecutive amino acid residues within the α-3 helix region were 
replaced with alanine residues (alanine scanning). We found that the 
mutant 56AAA58, in which amino acid residues 56-58 were replaced with 
alanine residues, did not interact with Alix. Furthermore, only this mutant 
did not cause core-VLP release, indicating that interaction with Alix is 
important for core-VLP release.  
We analyzed C-terminal ARD deletion mutants and found that 
complete deletion of ARD inhibited core-VLP release, indicating a role of 
this region for core-VLP release. We next analyzed ARD charge mutants in 
which abundant positively charged arginine residues were converted to 
negatively charged glutamic acids (core-RtoE) or the ARD domain was 
replaced with neutral charged HA tags (core-HA) or a glycine-rich linker 
(core-Gs) of a similar length. Core-RtoE completely lacked release and core-
HA and core-Gs partially lacked release, showing charge-dependent ability 
to aid core-VLP release. The Blue-Native PAGE method was used to 
investigate whether the core protein formed a multimer or not. Large 
amounts of monomers and oligomers were observed in Core-GtoE, indicating 
a failure of nucleocapsid assembly. Smaller amounts of monomers and 
oligomers were found in core-HA and core-Gs mutants. Although the ARD 
domain positive charge is thought to be important for holding viral genomic 
DNA, the charge may also be involved in core assembly and subsequent 
core-VLP budding. Similar failure of assembly was also observed in the 
complete ARD deletion mutant and the 56AAA58 mutant. These results 
suggest that proper capsid assembly is a prerequisite for core-VLP release. 
The results further suggest that there is link between capsid assembly and 
binding of the core protein with Alix, which remains to be elucidated. 
The use of VLP formation by the S protein revealed that release of 
S-VLPs, which are similar to subviral particles, was inhibited by tetherin. 
We showed the possibility that S-VLPs protect mature infectious virus 
particles from an interferon-inducible anti-viral protein, tetherin. The core-
VLP release itself is an enigma. For the release of core-VLPs, prior assembly 
to a capsid was shown to be necessary. Involvement of Alix in the core-VLP 
release was shown, but the detailed mechanism is still unknown.  
 
 
